SCHEMBL2938700

SCHEMBL2938700

Nc1nc(CNC2CC2)c2nc[nH]c2n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 2/20 0.35
CDK1 P06493 4/20 0.34
CCNB1 P14635 4/20 0.34
CCNA2 P20248 4/20 0.34
CDK2 P24941 4/20 0.34
CCNA1 P78396 4/20 0.34
MAP4K4 O95819 4/20 0.34
LMNA P02545 1/20 0.33
GBA1 P04062 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CNR1 P21554 1/20 0.33
TBXA2R P21731 1/20 0.33
HRH2 P25021 1/20 0.33
SLC6A4 P31645 1/20 0.33
KCNH2 Q12809 1/20 0.33
HIF1A Q16665 1/20 0.33
CYP3A4 P08684 1/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9683223 0.79 DHFR (0.37) CDK1CCNB1CCNA2CDK2CCNA1
SCHEMBL2938701 0.78 CDK2 (0.49) CDK1CCNB1CCNA2CDK2CCNA1
SCHEMBL5554962 0.75 CDK1 (0.49) CDK1CCNB1CCNA2CDK2CCNA1
SCHEMBL12844134 0.74 HEXA (0.37) CDK1CCNB1CCNA2CDK2CCNA1
SCHEMBL30590050 0.74 CHUK (0.45) LMNA
SCHEMBL133156 0.74 CHUK (0.45) LMNA
SCHEMBL25049931 0.73 CDK2 (0.46) CDK1CCNB1CCNA2CDK2CCNA1
Hydrochloric Acid SCHEMBL8971259 0.73 CHUK (0.44) LMNA
SCHEMBL17485430 0.71 KDM4A (0.43) GHSRCDK1CCNB1CCNA2CDK2
SCHEMBL5561179 0.70 ADORA2A (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118931997-A Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis 上海飞腾医药科技有限公司 2024-11-12 CN disclosed
EP-1925675-B1 Process for production of nucleoside compound MITSUI CHEMICALS INC (JP) 2010-02-03 EP disclosed
EP-1338654-B1 PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND MITSUI CHEMICALS INC (JP) 2008-10-15 EP disclosed
US-7381820-B2 α-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2′-deoxy-2′-fluoro-β-d-arabinonucleoside YAMASA CORPORATION (JP) 2008-06-03 US disclosed
EP-1178051-B1 PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE MITSUI CHEMICALS INC (JP) 2008-05-28 EP disclosed
EP-1925675-A1 Process for production of nucleoside compound Mitsui Chemicals, Inc. (JP) 2008-05-28 EP disclosed
US-20070135627-A1 Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside KOHEL YAMADA, ETAL 2007-06-14 US disclosed
EP-1676853-A1 ALPHA-1-PHOSPHORYLATED-2-DEOXY-2-FLUOROARABINOSIDE AND PROCESS FOR PRODUCING 2 -DEOXY-2 -FLUORO-BETA-D-ARABINONUCLEOSID E YAMASA CORPORATION (JP) 2006-07-05 EP disclosed
US-20060094869-A1 Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside MITSUI CHEMICALS, INC. (JP) 2006-05-04 US disclosed
US-7038039-B2 Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside MITSUI CHEMICALS, INC. (JP) 2006-05-02 US disclosed
EP-1179598-A1 PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND Mitsui Chemicals, Inc. (JP) 2002-02-13 EP disclosed
EP-1178051-A2 PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE Mitsui Chemicals, Inc. (JP) 2002-02-06 EP disclosed
EP-1177201-A1 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES YAMASA CORPORATION (JP) 2002-02-06 EP disclosed
EP-1177202-A1 4'-C-ETHYNYL PURINE NUCLEOSIDES YAMASA CORPORATION (JP) 2002-02-06 EP disclosed
US-6333315-B1 FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) YAMASA CORPORATION (JP) 2001-12-25 US disclosed
US-6291670-B1 VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) YAMASA CORPORATION (JP) 2001-09-18 US disclosed
WO-2000069877-A1 4'-C-ETHYNYL PURINE NUCLEOSIDES YAMASA CORPORATION (JP) 2000-11-23 WO disclosed
WO-2000069876-A1 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES YAMASA CORPORATION (JP) 2000-11-23 WO disclosed
US-6103707-A TREATMENT OF HERPES SIMPLEX VIRUS 1 (HSV-1), HERPES SIMPLEX VIRUS 2 (HSV-2), HUMAN CYTOMEGALOVIRUS (HCMV) AND VARICELLA-ZOSTER VIRUS YAMASA CORPORATION (JP) 2000-08-15 US disclosed
EP-0839813-A1 9-(2-DEOXY-2-FLUORO-4-THIO-BETA-D-ARABINOFURANOSYL)PURINE DERIVATIVES YAMASA CORPORATION (JP) 1998-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094869-A1 Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside PNP, MTAP, GALE GHSR 3191/4885CDK1 395/4885CCNB1 1813/4885
US-20070135627-A1 Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside TYMP, PNP, DUT GHSR 4758/4885CDK1 305/4885CCNB1 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.